[1
]
Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy
in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan
Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación
Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
[2
]
Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy
in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan
Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación
Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hereditary Cancer Program, Program
for Predictive and Personalized Medicine of Cancer-Germans Trias i Pujol Research
Institute (PMPPC-IGTP), Badalona, Spain.
[3
]
Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy
in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan
Institute of Oncology, l'Hospitalet del Llobregat, Spain; Hereditary Cancer Program,
Program for Predictive and Personalized Medicine of Cancer-Germans Trias i Pujol Research
Institute (PMPPC-IGTP), Badalona, Spain.
[4
]
Hereditary Cancer Program, Catalan Institute of Oncology, Girona Institute for Biomedical
Research (IDIBGi), Girona, Spain.
[5
]
Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Vall
d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
[6
]
Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy
in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan
Institute of Oncology, l'Hospitalet del Llobregat, Spain.
[7
]
Medical Oncology Department, Arnau de Vilanova University Hospital, Lleida, Spain.
[8
]
Department of Pathology, Bellvitge University Hospital, Catalan Institute of Oncology,
l'Hospitalet del Llobregat, Spain.
[9
]
Medical Oncology Department, Parc Taulí University Hospital, Sabadell, Spain.
[10
]
Medical Oncology Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain.
[11
]
Department of Pathology, General University Hospital of Catalonia, QuironSalud Group,
Sant Cugat del Vallès, Spain.
[12
]
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Department
of Pathology, Bellvitge University Hospital, IDIBELL, University of Barcelona, Barcelona,
Spain; Department of Pathology, Arnau de Vilanova University Hospital, Lleida Institute
for Biomedical Research (IRBLleida), University of Lleida, Lleida, Spain.
[13
]
Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy
in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan
Institute of Oncology, l'Hospitalet del Llobregat, Spain; Gerald Bronfman Department
of Oncology, McGill University, Montreal, Quebec, Canada.
[14
]
Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy
in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan
Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación
Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain; Hereditary Cancer Program, Catalan
Institute of Oncology, Girona Institute for Biomedical Research (IDIBGi), Girona,
Spain.
[15
]
Hereditary Cancer Program, Program in Molecular Mechanisms and Experimental Therapy
in Oncology (Oncobell), Bellvitge Institute for Biomedical Research (IDIBELL), Catalan
Institute of Oncology, l'Hospitalet del Llobregat, Spain; Centro de Investigación
Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Electronic address: clazaro@iconcologia.net.